ARMOR

Advanced Resilient Microbiome Optimization for Readiness (ARMOR)

1. What are you trying to do?

Develop an integrated testing/treatment platform for warfighters to monitor and optimize gut microbiome-driven readiness and performance while minimizing microbiome-driven risks associated with deployment. This program is expected to reduce lost duty days, injuries, infections, and cognitive symptoms by targeting six gut-brain axis domains: cognition, stress resilience, sleep, immune function, nutrient metabolism, and psychological health.

2. How is it done today, and what are the limitations?

Current performance optimization relies on generalized nutrition, pharmaceuticals, or wearable physiology sensors. These approaches:

  • Lack of precision in capturing dynamic microbiome-host interactions.
  • Provide limited mechanistic insights into stress resilience, fatigue, and cognitive decline.
  • Offer reactive rather than proactive interventions.
  • No existing system integrates microbiome diagnostics with targeted therapeutics to directly modulate human performance.
  • No single technique identifies actionable biomarkers or therapeutic targets

3. What’s new in your approach, and why will it succeed?

  • First effort to systematize biomarker and therapeutic discovery in microbiome science with metaproteomics and causal AI to reveal actionable biomarkers of performance.
  • The first low-cost, rapidly deployable point-of-care diagnostics (multiplex lateral flow immunoassay (mLFIAD) ) for microbiome-linked risk scores for real-time soldier readiness decisions.
  • Low-cost, precision soldier optimization therapeutics based on GRAS ingredients to restore resilience and enhance physiological output.
  • Closed-loop solution linking diagnostics → intervention → performance metrics.

4. Who cares?

  • Military: Enhanced soldier readiness, stress resilience, and cognitive performance in extreme battlefield conditions.
  • First responders/athletes: Resilience under high stress and variable environments.
  • Healthcare: Dual-use applications in chronic fatigue, PTSD, and immune dysfunction.

5. What are the risks, and how will you mitigate them?

  • Complexity of microbiome and individual variability: Use AI-driven multi-omics analysis, large diverse cohorts, and validation in controlled intestinal enteroid models to find robust protein-based pathways
  • Therapeutic safety: Focus on FDA GRAS ingredients, IgY (non-human origin but safe), and phased translational studies.
  • Field feasibility: AI-driven multi-omics analysis identifies key microbial proteins that serve as biomarkers, which are then targeted by IgY antibodies and incorporated into an mLFIAD for rapid, field-ready diagnostics.

6. How much will it cost and take?

TaskDescriptionCostDuration
DiscoveryProof-of-concept, metaproteomics analysis, biomarker discovery, therapeutic target identification, prototype mLFIAD diagnostic device$4.5–6.5M36 months
mLFIADsDevelopment of Final Device Format and V&V$2.5–3.5M24 months
Therapeutics
   Pre-ClinicalPreclinical Development $3-4M12 months
   Phase ISingle-site, 20–60 subjects$5-7M18 months
   Phase IIaMulti-site, 100–200 patients$14-16M24 months

Task: Discovery

Description: Proof-of-concept, metaproteomics analysis, biomarker discovery, therapeutic target identification, prototype mLFIAD diagnostic device

Cost: $4.5–6.5M

Duration: 36 months

Task: mLFIADs

Description: Development of Final Device Format and V&V

Cost: $2.5–3.5M

Duration: 24 months

Task: Therapeutics

Pre-Clinical

Description: Preclinical Development

Cost: $9-12M

Duration: 12 months

Phase I

Description: Single-site, 20–60 subjects

Cost: $3-4M

Duration: 18 months

Phase IIa

Description: Multi-site, 100–200 patients

Cost: $12-15M

Duration: 24 months

7. What are the midterm and final “exams” to check progress?

  • Year 1.5: Identify reproducible microbiome biomarkers predictive of cognitive and immune decline.
  • Year 3.0: Demonstrate rapid, field-deployable diagnostic detecting microbiome states in <30 minutes.
  • Year 5: IND-Enabled Studies complete with data package

Contact Us

Evimero’s Our AI-powered discovery platform can solve many of the world’s most challenging biological problems.